The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors
Escobar M, Castaman G, Boix S, Callaghan M, de Moerloose P, Ducore J, Hermans C, Journeycake J, Leissinger C, Luck J, Mahlangu J, Miesbach W, Mitha I, Négrier C, Quon D, Recht M, Schved J, Shapiro A, Sidonio R, Srivastava A, Stasyshyn O, Vilchevska K, Wang M, Young G, Alexander W, Al‐Sabbagh A, Bonzo D, Macie C, Wilkinson T, Kessler C. The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia 2021, 27: 921-931. PMID: 34636112, PMCID: PMC9292935, DOI: 10.1111/hae.14419.Peer-Reviewed Original ResearchConceptsEptacog betaTreatment of bleedingB patientsBleeding episodesHemophilia ASafety profileHemophilia patientsProspective phase 3 clinical trialsManagement of bleeding episodesPhase 3 clinical trialsTreat bleeding episodesPhase 3 trialControl of bleedingExcellent safety profilePaediatric haemophilia patientsPerioperative haemostasisPreoperative infusionClinical responseRandomized crossover designPerioperative useThrombotic eventsPost-operativelyData monitoring committeeFDA approvalPerioperative care
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply